NewsEvents

Your Yourlocation: Home > Effect of tiotropium bromide(136310-93-5) and salmeterol in the treatment of moderate to severe chronic obstructive pulmonary disease

To evaluate the clinical efficacy of tiotropium bromide(136310-93-5) and salmeterol in the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The study indicates that the combination of tiotropium and salmeterol in the treatment of moderate to severe stable chronic obstructive pulmonary disease is significantly better than the single drug, to promote the clinical application. The article published on "Journal of Clinical and Experimental Medicine."

A total of 165 patients with chronic obstructive pulmonary disease (COPD) who were treated during October 2011 to October 2013 were randomly divided into single drug A group and single drug B group and combined treatment group. All the patients were treated with single drug group A And tiotropium bromide(136310-93-5) powder inhalation. In the combination group, inhalation of salmeterol and fluticasone powder inhalation and inhalation of tiotropium bromide(136310-93-5) powder inhalation, all patients were treatment for 3 months. The clinical symptoms, lung function and quality of life were analyzed before and after treatment.

In this study, 165 patients were eventually required to implement a total of 163 cases of treatment. The FEV1, FEV1 /FVC and FEV1 /predicted values ??of the clinical symptoms, daily life, social life and mental life of each group after treatment were significantly better than those before treatment (P <0.05). The combination of drugs (P <0.05). Conclusion: The above-mentioned indexes in the group A and group B were significantly improved compared with those in group A and group B (P <0.05).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved